Monopar Therapeutics (MNPR) Research & Development (2017 - 2025)

Monopar Therapeutics (MNPR) has 9 years of Research & Development data on file, last reported at $2.6 million in Q3 2025.

• For the quarter ending Q3 2025, Research & Development rose 163.11% year-over-year to $2.6 million; the trailing twelve-month figure through Sep 2025 stood at $7.5 million (up 70.12% YoY), and the FY2024 full-year result was $4.6 million, changed N/A from the prior year.
• Research & Development grew to $2.6 million in Q3 2025, from $1.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $2.6 million in Q3 2025 to a low of $966110.0 in Q1 2024.
• A 5-year average of $1.6 million and a median of $1.6 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 250.39% in 2021 and tumbled 41.57% in 2024, its largest moves.
• Tracing MNPR's Research & Development over 5 years: stood at $2.0 million in 2021, then climbed by 6.07% to $2.1 million in 2022, then slumped by 37.4% to $1.3 million in 2023, then climbed by 15.35% to $1.5 million in 2024, then jumped by 70.53% to $2.6 million in 2025.
• Business Quant data shows MNPR's Research & Development at $2.6 million in Q3 2025, $1.7 million in Q2 2025, and $1.6 million in Q1 2025.